Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser; Manuela Krumbholz; Christian Thiede; Josephine T. Tauer; Indra Janz; Melchior Lauten; Dagmar Dilloo; Markus Metzler; Meinolf Suttorp

doi:10.1002/pbc.25090

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser, Manuela Krumbholz, Christian Thiede, Josephine T. Tauer, Indra Janz, Melchior Lauten^*, Dagmar Dilloo, Markus Metzler, Meinolf Suttorp

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Kinder- und Jugendmedizin

6 Zitate (Scopus)

Abstract

Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

Originalsprache	Englisch
Zeitschrift	Pediatric Blood and Cancer
Jahrgang	61
Ausgabenummer	11
Seiten (von - bis)	2080-2082
Seitenumfang	3
ISSN	1545-5009
DOIs	https://doi.org/10.1002/pbc.25090
Publikationsstatus	Veröffentlicht - 01.11.2014

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.1002/pbc.25090

Weitere Links

Link to publication in Scopus

Zitieren

@article{09c3f0d4eb3941dcb499e39285b9f3cc,

title = "Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia",

abstract = "Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.",

author = "Olga Moser and Manuela Krumbholz and Christian Thiede and Tauer, {Josephine T.} and Indra Janz and Melchior Lauten and Dagmar Dilloo and Markus Metzler and Meinolf Suttorp",

year = "2014",

month = nov,

day = "1",

doi = "10.1002/pbc.25090",

language = "English",

volume = "61",

pages = "2080--2082",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "11",

}

TY - JOUR

T1 - Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

AU - Moser, Olga

AU - Krumbholz, Manuela

AU - Thiede, Christian

AU - Tauer, Josephine T.

AU - Janz, Indra

AU - Lauten, Melchior

AU - Dilloo, Dagmar

AU - Metzler, Markus

AU - Suttorp, Meinolf

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

AB - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

UR - http://www.scopus.com/inward/record.url?scp=84915736394&partnerID=8YFLogxK

U2 - 10.1002/pbc.25090

DO - 10.1002/pbc.25090

M3 - Journal articles

C2 - 24810322

AN - SCOPUS:84915736394

SN - 1545-5009

VL - 61

SP - 2080

EP - 2082

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

ER -

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Abstract

Strategische Forschungsbereiche und Zentren

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren